ALS News Today: Investigational Treatment IPL344 Safely Slows ALS Progression in Small Phase 1/2a Trial

IPL344, Immunity Pharma‘s investigational therapy for amyotrophic lateral sclerosis (ALS), has a positive safety and tolerability profile and slows disease progression by about 50%, according to interim results from a small Phase 1/2a clinical trial.